Review
doi: 10.1016/j.euroneuro.2015.08.019. Epub 2015 Sep 7.A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature
Affiliations
- PMID:26527055
- DOI: 10.1016/j.euroneuro.2015.08.019
Item in Clipboard
Review
A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature
Joseph Zohar et al. Eur Neuropsychopharmacol.2015 Dec.
Display options
Format
Display options
Format
Abstract
Neuroscience based Nomenclature (NbN) is a new system of classifying psychotropic drugs by their pharmacological profile. The NbN was developed to replace the current indication-based nomenclature and to provide an up-to-date and more useful framework to better inform pharmacological decisions. NbN provides updated relevant and specific scientific, regulatory and clinical information, aiming to support rational and lucid prescribing. This pharmacologically driven nomenclature, which highlights pharmacological domains and modes of action, may also increase drug adherence as it clarifies the rationale for selecting a specific psychotropic agent.
Keywords: Adherence; Mode of action; Neuroscience; Nomenclature; Pharmacological domain; Psychotropic drugs.
Copyright © 2015. Published by Elsevier B.V.
Similar articles
- A new nomenclature for classifying psychotropic drugs.Caraci F, Enna SJ, Zohar J, Racagni G, Zalsman G, van den Brink W, Kasper S, Koob GF, Pariante CM, Piazza PV, Yamada K, Spedding M, Drago F.Caraci F, et al.Br J Clin Pharmacol. 2017 Aug;83(8):1614-1616. doi: 10.1111/bcp.13302. Epub 2017 May 24.Br J Clin Pharmacol. 2017.PMID:28401576Free PMC article.
- Neuroscience-based nomenclature (jNbN) to replace traditional terminology of psychotropic medications.Möller HJ, Schmitt A, Falkai P.Möller HJ, et al.Eur Arch Psychiatry Clin Neurosci. 2016 Aug;266(5):385-6. doi: 10.1007/s00406-016-0699-0.Eur Arch Psychiatry Clin Neurosci. 2016.PMID:27216433No abstract available.
- [Newly developed nomenclature (Neuroscience-based Nomenclature)].Uchida H, Yamawaki S.Uchida H, et al.Nihon Shinkei Seishin Yakurigaku Zasshi. 2016 Jun;36(3):69-71.Nihon Shinkei Seishin Yakurigaku Zasshi. 2016.PMID:27506083Japanese.
- A proposed system for classifying psychotropic drugs.Howland RH.Howland RH.J Psychosoc Nurs Ment Health Serv. 2014 Dec 1;52(12):13-5. doi: 10.3928/02793695-20141118-05.J Psychosoc Nurs Ment Health Serv. 2014.PMID:25453506Review.
- Herbal medicine for psychiatric disorders: Psychopharmacology and neuroscience-based nomenclature.Tang SW, Tang WH, Leonard BE.Tang SW, et al.World J Biol Psychiatry. 2019 Oct;20(8):586-604. doi: 10.1080/15622975.2017.1346279. Epub 2017 Jul 11.World J Biol Psychiatry. 2019.PMID:28649903Review.
Cited by
- Neuroscience-based Nomenclature (NbN): A call for action.Zohar J, Kasper S.Zohar J, et al.World J Biol Psychiatry. 2016 Aug;17(5):318-20. doi: 10.1080/15622975.2016.1193626. Epub 2016 Jul 5.World J Biol Psychiatry. 2016.PMID:27379490Free PMC article.No abstract available.
- Changing the Antipsychotic in Early Nonimprovers to Amisulpride or Olanzapine: Randomized, Double-Blind Trial in Patients With Schizophrenia.Heres S, Cordes J, Feyerabend S, Schmidt-Kraepelin C, Musil R, Riedel M, Spellmann I, Langguth B, Landgrebe M, Fran E, Petcu C C, Hahn E, Ta TMT, Matei V, Dehelean L, Papava I, Leweke FM, van der List T, Tamasan SC, Lang FU, Naber D, Ruhrmann S, Wolff-Menzler C, Juckel G, Ladea M, Stefanescu C, Lautenschlager M, Bauer M, Zamora D, Horowitz M, Davis JM, Leucht S.Heres S, et al.Schizophr Bull. 2022 Nov 18;48(6):1273-1283. doi: 10.1093/schbul/sbac068.Schizophr Bull. 2022.PMID:35857811Free PMC article.Clinical Trial.
- Serotonin-2B receptor antagonism increases the activity of dopamine and glutamate neurons in the presence of selective serotonin reuptake inhibition.Hamati R, El Mansari M, Blier P.Hamati R, et al.Neuropsychopharmacology. 2020 Nov;45(12):2098-2105. doi: 10.1038/s41386-020-0723-y. Epub 2020 May 30.Neuropsychopharmacology. 2020.PMID:32473594Free PMC article.
- Psychedelic Therapy's Transdiagnostic Effects: A Research Domain Criteria (RDoC) Perspective.Kelly JR, Gillan CM, Prenderville J, Kelly C, Harkin A, Clarke G, O'Keane V.Kelly JR, et al.Front Psychiatry. 2021 Dec 17;12:800072. doi: 10.3389/fpsyt.2021.800072. eCollection 2021.Front Psychiatry. 2021.PMID:34975593Free PMC article.Review.
- Antidepressive Effect of Antipsychotics in the Treatment of Schizophrenia: Meta-Regression Analysis of Randomized Placebo-Controlled Trials.Miura I, Nosaka T, Yabe H, Hagi K.Miura I, et al.Int J Neuropsychopharmacol. 2021 Mar 17;24(3):200-215. doi: 10.1093/ijnp/pyaa082.Int J Neuropsychopharmacol. 2021.PMID:33151310Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous